Lawsuits related to the painkiller Vioxx have little prospect of resolution for the thousands who have sued the drug company Merck, it was reported.
An estimated 45,000 people have sued Merck, contending the drug caused heart attacks and strokes. Merck has spent more than $1 billion on legal fees during the last three years on Vioxx cases and has vowed to contest each lawsuit, The New York Times reported Tuesday.
Merck, the third-largest U.S. drug maker, is betting its aggressive resistance will reduce the number of cases and, ultimately, its liability, the Times reported. The result is a legal limbo in which even those who have won a case against Merck have yet to see any money because Merck immediately appeals, the newspaper said.
Estimates of Merck's liability, once as high as $25 billion, now is closer to $5 billion, corporate risk analysts told the Times.
Copyright 2007 by United Press International
Related stories:
FDA proposal on drug articles under fire
Claims that the pharmaceutical company Merck hired ghostwriters for Vioxx articles has put heat on a U.S. proposal to loosen drug promotion rules.
Too much information? Study shows how ignorance can be influential
In the current issue of
The RAND Journal of Economics, USC researchers provide a challenge to the classic economic model of information manipulation, in which knowing more than anybody else is the key to influence.
FDA pans Merck's new pain pill
The U.S. Food and Drug Administration has rejected Merck's bid to sell the pain medication Arcoxia in the United States.
Study finds that vioxx reduces the risk of colorectal polyps
A researcher from Dartmouth reports the results of a clinical trial that shows that the cyclooxygenase-2 (COX-2) inhibitor rofecoxib (VIOXX®) reduces the risk of colorectal adenomas, or polyps. Polyps are benign tumors that are precursors to colon cancer, and they are often found in older adults.
Study: Vioxx poses even short-term risks
A Montreal study raises questions about even short-term use of the pain drug Vioxx and may harm Merck & Co.'s defense against 11,500 lawsuits, a report said.
Researchers target silicon chips for biomolecular devices
Arizona State University researchers in the Ira A. Fulton School of Engineering are key contributors to an $11.7 million, multicollaborative Defense Advanced Research Project Agency research project developing novel hybrid biomolecular nanodevices and systems for potential application as biosensors in areas such as disease detection, pharmaceutical drug-testing, drug-delivery systems and health monitoring.
A light bulb and a few chemicals: Scientists find a way to help make new reactions
(PhysOrg.com) -- Princeton scientists have discovered a way of stimulating organic molecules that they expect will prompt researchers to create materials from new kinds of chemical reactions.
Doctors say Vytorin-cancer link can't be ruled out
(AP) -- Results from three studies of the cholesterol-lowering drug Vytorin are not enough to prove or rule out a possible link to a higher risk of cancer, so the drug should be used with great caution until more is known, editors of a leading medical journal urged Tuesday.